Indoco Remedies announced today that the US Food and Drug Administration (FDA) has successfully completed inspection of its Active Pharmaceutical Ingredients (API) manufacturing facility at Patalganga, Navi Mumbai. The inspection concluded with zero form 483 observations, reflecting the company's commitment to the highest standards of quality, regulatory compliance and operational excellence.

Aditi Panandikar, Managing Director, Indoco Remedies, said, “This successful US FDA inspection is a testament to the strong quality culture and compliance in every process and every product. We remain committed to strengthen our systems to deliver safe and efficacious medicines across the globe.”

Indoco is a fully integrated, research-oriented pharmaceutical company with a strong global presence. The company’s turnover is USD 180 million with a human capital of more than 6,000 employees, including over 400 skilled scientists and field staff who are the strength of the organisation.